Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (3326)	1/29/2001 4:35:21 PM
From: Jenna	Read Replies (1) \| Respond to of 6445

IDPH ---- Third Consecutive Year of Profitability Reported by IDEC Pharmaceuticals Revenue Growth of 31 Percent for Year 2000 SAN DIEGO--(BW HealthWire)--Jan. 29, 2001--IDEC Pharmaceuticals Corporation (Nasdaq:IDPH - news) today announced its financial results for the fourth quarter and year ended December 31, 2000. Total annual revenues were $154.7 million, a $36.7 million, or 31 percent increase over 1999 revenues of $118.0 million. The company reported net income of $48.1 million, or $0.30 per share on a diluted basis in 2000, versus net income of $43.2 million, or $0.29 per share on a diluted basis for the same period in 1999. IDEC's fourth quarter and full year results for both 2000 and 1999 have been adjusted to reflect IDEC's three-for-one stock split in January 2001 and implementation of the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 101. If IDEC had not implemented SAB No. 101, the reported earnings per share on a diluted basis would have been $0.33 per share for the year ended December 31, 2000.